Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 2019-02-11
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.36%+44.08%+102.76% 68.24B
+1.08%-3.13%+32.19%+76.04% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
+0.19%-3.42%+14.80%-19.33% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -0.91%-3.30%+39.26%+171.53% 30.3B
Weighted average by Cap. -0.46%-3.10%+35.76%+137.13%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!